1

2
WITOWSKI Steven Richard, WESTLIN III William Frederick, TESTER Richard Wayne: Sel de bésylate dun inhibiteur de btk, Besylate salt of a btk inhibitor. Avila Therapeutics, WITOWSKI Steven Richard, WESTLIN III William Frederick, TESTER Richard Wayne, ROBIDOUX Andrea L C, February 16, 2012: WO/2012/021444 (73 worldwide citation)

The present invention provides a salt form, and compositions thereof, useful as an inhibitor of one or more protein kinases and which exhibits desirable characteristics for the same.


3

4
SINGH JUSWINDER: Heteroaryl compounds and uses thereof. AVILA THERAPEUTICS, Huck Emilie Porter, July 28, 2011: WO/2011/090760 (57 worldwide citation)

The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.


5
SINGH JUSWINDER: Protein kinase conjugates and inhibitors. AVILA THERAPEUTICS, Underwood Robert H, March 24, 2011: WO/2011/034907 (50 worldwide citation)

The invention relates to protein conjugates that contain a protein kinase containgn a cysteine residue in the ATP binding site and an inhibitor that is covalently and irreversibly bonded to said cysteine residue, such that the activity of the protein kinase is irreversibly inhibited. The invention a ...


6

7
LEE Kwangho, NIU Deqiang, PETTER Russell C, SINGH Juswinder: COMPOSÉS HÉTÉROARYLE ET LEURS UTILISATIONS, HETEROARYL COMPOUNDS AND USES THEREOF. AVILA THERAPEUTICS, LEE Kwangho, NIU Deqiang, PETTER Russell C, SINGH Juswinder, BUTEAU Kristen C, May 10, 2012: WO/2012/061303 (33 worldwide citation)

Heterocyclic pynmidine compounds that modulate mutant-selective epidermal growth factor receptor (EGFR) kinase activity are disclosed. Selectivity in modulation of various EGFR mutant activity has been disclosed. Pharmaceutical compositions comprising the pynmidine derivative, and methods of treatme ...


8

9
LEE Kwangho, NIU Deqiang, PETTER Russell C, BAEVSKY Matthew Frank, SINGH Juswinder: COMPOSÉS HÉTÉROCYCLIQUES ET LEURS UTILISATIONS, HETEROCYCLIC COMPOUNDS AND USES THEREOF. AVILA THERAPEUTICS, LEE Kwangho, NIU Deqiang, PETTER Russell C, BAEVSKY Matthew Frank, SINGH Juswinder, BUTEAU Kristen C, May 10, 2012: WO/2012/061299 (32 worldwide citation)

Heterocyclic pyrimidine compounds that modulate mutant-selective epidermal growth factor receptor (EGFR) kinase activity are disclosed. Selectivity in inhibition of various mutant-EGFR is disclosed. Pharmaceutical compositions containing the pyrimidine derivatives, and methods of treating diseases a ...


10